Philman's Pharm: "German Quality, California Ingenuity." Est. 1977

Leave a comment

The UN Commission of Narcotic Drugs (CND) will receive the final scheduling recommendations of the World Health Organization (WHO) on cannabis in all forms to the 187 Member States at the United Nations Office on Drugs and Crime (UNODC) headquarters in Vienna, Austria on December 5-7, 2018.

More info here:
Philip J. Cenedella IV
Skype: philip.j.cenedella
Phones:   +49.151.720.17652
+1.888.206.3264 USA

German Tax No.: 38/108/04462

VAT No.:  DE313501847

CONFIDENTIAL COMMUNICATION: E-mails from this individual normally contain confidential and privileged material, and are for the sole use of the intended recipient. Use or distribution by an unintended recipient is prohibited. If you believe that you received this e-mail in error, please delete. Electronic Communications Privacy Act, 18 U.S.C. 2510-2521. Thanks.  Copyright © 2018 GERMAN PATIENT ROUNDTABLE – All Rights Reserved.   ** Your personal data will never be shared with anyone, …never.  The German Patient Roundtable is dedicated to Ras Manos, R.I.P.

GERMANY: Cannamedical Pharma is seeking significant damages against Aurora Cannabis Inc. and MedReleaf Corp. for failure to deliver on a promised 100 kilograms of cannabis products.


According to the statement of claim filed with the Superior Court of Justice in Ontario, Cannamedical Pharma is seeking significant damages against Aurora Cannabis Inc. and MedReleaf Corp. for failure to deliver on a promised 100 kilograms of cannabis products per month.  In May of 2018, MedReleaf announced the monthly supply agreement with Cannamedical, touting the deal as a way to “significantly [improve] the predictability and security of drug delivery to the German market.”  While an initial order of 33 kilograms of cannabis was delivered, a second order for 23 kilograms of product was reportedly sold to another customer and no replacement product was made available.  The Canadian LP failed to deliver on two subsequent purchase orders (amounting to 126 kilograms of cannabis) submitted for August and September despite assurances that future batches were earmarked for the German market.




HOLLAND: Coffeeshop owners do not want to participate in the experiment of selling farm-grown cannabis

PhilmansPharmLogo small

According to Josemans, Maastricht’s coffee shops, which are already plagued by strict local politics, would hardly make ends meet economically if they embark on the experiment with all the imponderables and consequences. “This is not an experiment, but a deliberate approach to stifle any possibility of success,” writes Josemans on behalf of the Maastricht coffee shops.  Instead, the owners plead for the cultivation and distribution of cannabis on the American model. “If we look at the positive results of legalization in countries like Uruguay, some American states and Canada, there is only one choice: legalization. We do not have to reinvent the wheel here, if things are already going well there: Let’s take one of these countries as a model and get to work. ”  


Michael Knodt of DHV – English version of article on ABDA – German pharmacies MUST charge 100% markup – average cost of one gram is now 24 euro each ($27.21 USD, 35.97 CAD)


michal knodt

Patients have been reporting recently about pharmacies that have raised prices for cannabis flos for fear of financial and professional consequences. Specifically, this is about cases from Bavaria, Baden-Württemberg and North Rhine-Westphalia. The Federal Association of German Pharmacists Associations (ABDA) has now confirmed on request that pharmacies that deliver cannabis without fully charge the currently hotly debated surcharges risk prosecution by the respective state pharmacy chamber. Four simultaneous inquiries from the pharmacy chambers of Bavaria, Baden-Württemberg, North Rhine-Westphalia (Lippe) and the Federal Chamber of Pharmacists (BAK) have consistently revealed that cannabis currently has to be sold for around 24 euros per gram,

The deputy spokeswoman of the ABDA, Dr. med. Ursula Sellerberg, writes in a letter dated October 29, that the system of price formation in the drug price regulation is clearly regulated and is the same for all pharmacies. In the case of a medical prescription for cannabis flowers, these are considered as prescription medicines according to the Pharmacist Order (ApBetrO). If they are then transferred, bottled, packaged or labeled in their unmodified state and handed over to the patient, a premium of 100% is to be charged in accordance with §4 AmPreisV. If the cannabis flowers are additionally shredded, sieved or packed in single doses, the 90% premium must be calculated according to the New Formulation Form (NRF) regulations, to which various fees are added.

Three and a half times as expensive as in the neighboring country

Here are two examples for clarification. To keep it simple, we are assuming a pharmacy purchase price of ten euros. This value comes pretty close to the real purchase price. However, the purchase price for pharmacies varies depending on the quantity and variety.

Patient A goes to the pharmacy with a prescription for 10 grams of cannabis XY. On the recipe the doctor added the word “uncrushed”. Thus the medicine is sold according to §4 of the AmPreisV. The pharmacist only provides the original cans with a label. In addition, the pharmacies can charge the narcotics fee according to §7 AMPreisV in the amount of 2.91 Euro including VAT. Patient A gets the 10 grams accordingly for 240.91 including 19% VAT.

100,00 € (purchase price of the pharmacy)

+ 100,00 € (prescribed surcharge of the pharmacy)

200.00 €

+ 38,00 € (19% VAT)

+ 2,91 € (Narcotics fee)

   240.91 €

Patient B goes to the pharmacy with a prescription for 10 grams of XY cannabis flowers. The word “unzerkleinert” is missing on the recipe. Now the flowers are crushed, divided into the single doses indicated on the order, repackaged and therefore sold according to §5 of the AmPreisV. The final price of 245.37 euros is then composed as follows:

100,00 € (purchase price of the pharmacy)

+ 90,90 € (90% surcharge according to $ 5 AmPreisV.)

+ 1,00 € (packaging)

+ 3,50 € (formula supplement)

+ 8,35 € (fixed surcharge for recipes) 203,75 €

+ € 38.71 (19% VAT)

+ 2,91 € (Narcotics fee)

  245.37 €

The only fee that pharmacies may waive without violating the AmPreisV is the narcotics fee of 2.91 per prescription submitted. This should give reason to think about the situation in the Netherlands, where the same medicine is being donated to the patient for seven euros, under similarly stringent safety regulations and similar laws. Meanwhile, there are already the first cases in which pharmacies were warned due to a patient-friendly pricing. According to ABDA and the other three chambers of the state, no pharmacy has yet to pay. However, this does not mean that any proceedings have already been initiated because the pharmacists’ associations do not provide any information about any ongoing proceedings. The ABDA spokeswoman confirms in her letter as well,

Bayern also emphasizes professional legal steps

A spokeswoman for the Bavarian pharmacy chamber adds that “in addition to the abduction mentioned by the ABDA, a professional punishment is added by the chamber.”   So far, such cases would not exist in Bavaria, but the Bavarian State Pharmacists’ Chamber should not give any specific information for data protection reasons.

A spokesman for the pharmacy associations Westfalen-Lippe confirms that the chamber has so far not been active in the matter. “Westfalen-Lippe has not been fined a violation of the drug price regulation; In this respect, for us as a chamber there has not yet been any so-called professional overhang which we would have to prosecute. “ The answer from Baden-Württemberg confirms the danger in which pharmacies that make cannabis cheaper than prescribed are in danger. Even there, “Violations of the Pharmaceutical Price Ordinance can have professional consequences. The extent to which consequences are to be expected from the monitoring authorities is not known to us, “ it says from the press office of the Landesapothekerkammer Baden-Württemberg.

The times when pharmacies were allowed to meet the patients, who often have to pay their own medical expenses, to meet patients by renouncing their own profits seem to be over for good.




Need CBD-flower suppliers, that cultivate medical cannabis CBD-buds, under supervision of the local country cannabis agency, for delivery to Europe. – serious inquiries only

REQUEST FROM CLIENT (send reply to phil@cenedella.de) :  Need CBD-flower suppliers, that cultivate medical cannabis CBD-buds, under supervision of the local country cannabis agency, for delivery to Europe.  – serious inquiries only


Together Germany

PhilmansPharmLogoB1 - Copy

The license is for importing, producing and distributing medical cannabis in Germany.

Together (TASE: TGDR), which specializes in cultivating and producing medical cannabis, has announced that the German company with which it signed a binding memorandum of understanding to acquire control of it, has received a wholesale commercial license for medications from Germany’s Federal Ministry of Health.The license allows the German company to import, produce and distribute narcotic treatments including medical cannabis, so that when acquisition of control in the German company is completed, Together will be allowed to import and distribute medical cannabis products in Germany from other international enterprises. As Germany is one of the main and largest markets in the medical cannabis market, Together believes that acquiring control of the German company will provide it with a major advantage over its rivals around the world, position it alongside the world’s leading producers and suppliers of medical cannabis, and help fulfill its strategy of creating revenue and profits from several countries worldwide. According to the German company’s declarations, it has reached a distribution agreement with a pharmacy chain, which owns more than 100 pharmacies in Germany.

Together CEO Nissim Bracha said, “Receipt of the license by the German company marks an important milestone for Together because with completion of acquisition of control in it, we will immediately be able to begin commercial operations in Europe. In addition to the license for trading in medical cannabis in Germany, we expect that immediately after signing the agreement to acquire control, we will work to import to Germany medical cannabis products from international enterprises, which we will sell and consolidate a significant foothold of operations that can operate throughout Europe.”

The company’s share price was up 4.58% in early afternoon trading on the TASE.